17^th Global Ophthalmology, Optometry and Glaucoma Conference

Future of glaucoma treatment and management

Numerous new improvements on the exploration front recommend the fight against glaucoma is turning. New medications are presently entering the center, alongside better approaches to convey them. There is developing agreement that the eventual fate of glaucoma administration will be construct more in light of the optic nerve pathway from the retina to the visual cortex, and not entirely constrained to enhancing outpouring. EuroTimes investigates what glaucoma treatment may look like not long from now.

Glaucoma illness can be controlled even with viable treatment, patients must have general eye examinations. Treatment frequently proceeds for the patient's lifetime. Albeit troublesome, long lasting treatment is desirable over vision misfortune. Bringing down the intraocular weight is the center of treating patients with glaucoma. Bringing IOP is done down to a level that is not prone to bring on additional optic nerve harm; this level is alluded to as the objective weight and is controlled by the ophthalmologist. High IOP may harm the optic nerve, which can prompt vision misfortune. The level varies for every patient, and a patient's objective weight may change over the span of a lifetime. For open-edge glaucoma (the most well-known sort), the ophthalmologist may recommend pharmaceutical to lower IOP. Topical or oral pharmaceuticals, embeds (waferlike portions of medicine that are placed toward the edge of the eye), or eye salves can be utilized.